Federal Register of Legislation - Australian Government

Primary content

PB 21 of 2012 Arrangements as made
This instrument amends the National Health (Botulinum Toxin Program) Special Arrangement 2011 (No. PB 89 of 2011) to make changes to the special arrangements relating to the Botulinum Toxin Program.
Administered by: Health
Registered 29 Mar 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 21 of 2012

National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2012 (No. 1)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated 26  March 2012

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


1          Name of Instrument

            (1)        This Instrument is the National Health (Botulinum Toxin Program)

                        Special Arrangement Amendment Instrument 2012 (No.1).

            (2)        This Instrument may also be cited as PB 21 of 2012.

2          Commencement

(1)       This instrument commences on 1 April 2012.

3          Amendment of PB 89 of 2011

            Schedule 1 amends the National Health (Botulinum Toxin Program) Special Arrangement 2011 (PB 89 of 2011).

4          Transitional

            A medical practitioner authorised under subsection 18(1) of PB 89 of 2011 immediately prior to the commencement of this instrument to administer botulinum toxin pharmaceutical benefits for the treatment condition ‘Treatment of blepharospasm or hemifacial spasm’ is, after the commencement of this Instrument, taken to be authorised to administer botulinum toxin pharmaceutical benefits for the treatment conditions ‘Treatment of blepharospasm or hemifacial spasm in a patient 12 years or older’ and ‘Treatment of blepharospasm or hemifacial spasm in an adult’.

 


 

 

 

 


Schedule 1     Amendments

[1]        Subsection 18(4), after spasm (first occurring)

insert:

in a patient 12 years or older and/or the treatment of blepharospasm or hemifacial spasm in an adult

[2]        Subparagraph 18(4)(b)(ii)

omit:

condition blepharospasm or hemofacial spasm

substitute:

conditions numbered 1 and/or 1A

[3]        Subsection 18(5), after spasm (first occurring)

insert:

in a patient 12 years or older and/or the treatment of blepharospasm or hemifacial spasm in an adult

[4]         Subparagraph 18(5)(b)(ii)

omit:

condition blepharospasm or hemofacial spasm

substitute:

conditions numbered 1 and/or 1A

[5]         Schedule 1, after

 

Botulinum Toxin Type A Purified Neurotoxin Complex

Lyophilised powder for injection 100 units

Injection

Botox

AG

D

insert:

Clostridium Botulinum Type A Toxin-Haemagglutinin Complex

Lyophilised powder for injection 300 units

Injection

Dysport

IS

D

[6]        Schedule 3

omit:

1

Treatment of blepharospasm or hemifacial spasm

Botulinum Toxin Type A Purified Neurotoxin Complex

Neurology

Opthalmology

Otolaryngology head and neck surgery

Plastic Surgery

substitute:

1

Treatment of blepharospasm or hemifacial spasm in a patient 12 years or older

Botulinum Toxin Type A Purified Neurotoxin Complex

Neurology

Opthalmology

Otolaryngology head and neck surgery

Plastic Surgery

1A

Treatment of blepharospasm or hemifacial spasm in an adult

Clostridium Botulinum Type A Toxin-Haemagglutinin Complex

Neurology

Opthalmology

Otolaryngology head and neck surgery

Plastic Surgery

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the

Legislative Instruments Act 2003.  See http://www.frli.gov.au.